Tonix publishes pharmacokinetic studies of fibromyalgia drug TONMYA Mar 5, 2026 04:15PM
Tonix Pharmaceuticals Announces Publication of Clinical Pharmacokinetic Studies of TONMYA™ and Prototype Formulations in the Journal Clinical Pharmacology in Drug Development Mar 5, 2026 04:15PM
Tonix Pharmaceuticals moves to NASDAQ Global Select Market Mar 3, 2026 06:01AM
Tonix Pharmaceuticals Announces Uplisting from Nasdaq Capital Market to Nasdaq Global Select Market Mar 3, 2026 06:00AM
Tonix Pharmaceuticals to Participate in Two Investor Conferences in March Feb 25, 2026 07:00AM
View Older Stories

Jan 30, 2026 07:00AM Tonix presents fibromyalgia drug data at pain therapeutics summit
Jan 30, 2026 07:00AM Tonix Pharmaceuticals Presented Phase 3 RESILIENT Data on TONMYA™ (Cyclobenzaprine HCl Sublingual Tablets) at the 2026 Non-Opioid Pain Therapeutics Summit
Jan 6, 2026 07:00AM Tonix Pharmaceuticals to Present at Two Investor Conferences in January 2026
Dec 29, 2025 07:57AM Tonix Pharmaceuticals prices $20 million registered direct offering
Dec 29, 2025 07:57AM Tonix Pharmaceuticals Announces Pricing of $20.0 Million Registered Direct Offering
Dec 29, 2025 07:45AM Tonix updates development plans for Lyme disease prevention antibody
Dec 29, 2025 07:45AM Tonix Pharmaceuticals Announces Program Updates on Phase 2/3-Ready Long-Acting Monoclonal Antibody (mAb) Designed for Seasonal Prevention of Lyme Disease (TNX-4800)
Dec 16, 2025 07:01AM Tonix licenses TNX-4900 neuropathic pain drug from Rutgers
Dec 16, 2025 07:00AM Tonix Pharmaceuticals Announces Licensing TNX-4900, a Selective Sigma-1 Receptor Antagonist for Chronic Neuropathic Pain from Rutgers University
Dec 9, 2025 07:00AM Tonix Pharmaceuticals Appoints Irina Ishak as General Counsel
Nov 24, 2025 07:00AM Tonix gets FDA clearance for major depression study of TNX-102 SL
Nov 24, 2025 07:00AM Tonix Pharmaceuticals Announces FDA IND Clearance for Phase 2 Study of TNX-102 SL for the Treatment of Major Depressive Disorder
Nov 10, 2025 04:15PM Tonix Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Highlights
Nov 6, 2025 07:00AM Tonix Pharmaceuticals to Participate in the Stifel 2025 Healthcare Conference
Nov 4, 2025 07:01AM Tonix partners with Mass General for kidney transplant drug trial
Nov 4, 2025 07:00AM Tonix Pharmaceuticals Announces Collaboration with Massachusetts General Hospital to Advance Phase 2 Clinical Trial of Dimeric Fc-modified anti-CD40L mAb, TNX-1500, to Prevent Kidney Transplant Organ
Oct 27, 2025 07:02AM Tonix presents fibromyalgia drug data at rheumatology conference
Oct 27, 2025 07:00AM Tonix Pharmaceuticals Presented Data on Tonmya™ (Cyclobenzaprine HCl Sublingual Tablets) at the 2025 American College of Rheumatology (ACR) Convergence
Oct 22, 2025 07:00AM Tonix Pharmaceuticals Announces First Patient Dosed in the Investigator-Initiated FOCUS Study of Tonix’s Intranasal Potentiated Oxytocin in AVP-D Conducted by Massachusetts General Hospital
Oct 21, 2025 07:00AM Tonix Pharmaceuticals to Present Poster on Tonmya™ at the 2025 American College of Rheumatology (ACR) Convergence
Oct 17, 2025 07:01AM Tonix presents mpox vaccine data at European conference
Oct 17, 2025 07:00AM Tonix Pharmaceuticals Presented Data on TNX-801 Mpox Vaccine at World Vaccine Congress–Europe 2025
Oct 14, 2025 07:03AM Tonix presents TNX-1500 data at Japan transplantation congress
Oct 14, 2025 07:00AM Tonix Pharmaceuticals Presented an Update on Fc-modified anti-CD40L mAb, TNX-1500, at the 61st Annual Congress of the Japan Society for Transplantation
Oct 9, 2025 07:00AM Tonix Pharmaceuticals to Present and Participate in Panel Discussion at World Vaccine Congress, Europe 2025
Sep 29, 2025 07:00AM Tonix Pharmaceuticals plans phase 2 trial for Prader-Willi syndrome drug
Sep 29, 2025 07:00AM Tonix Pharmaceuticals Plans to Initiate Prader-Willi Syndrome Phase 2 Trial of TNX-2900 (Intranasal Potentiated Oxytocin) in 2026
Sep 17, 2025 07:01AM Tonix licenses monoclonal antibody for Lyme disease prevention
Sep 17, 2025 07:01AM Tonix Pharmaceuticals Announces In-licensing Phase 2/3-Ready Monoclonal Antibody Designed for Seasonal Prevention of Lyme Disease (TNX-4800)
Sep 17, 2025 07:00AM Tonix Pharmaceuticals Announces In-licensing Phase 2/3-Ready Monoclonal Antibody Designed for Seasonal Prevention of Lyme Disease (TNX-4800)
Jul 21, 2025 07:00AM Tonix Pharmaceuticals Announces the Launch of the “Move Fibro Forward” Campaign to Bring Awareness to Individuals Impacted by Fibromyalgia
Jul 10, 2025 07:02AM Tonix presents data on mpox and smallpox vaccine candidate at Vienna congress
Jul 10, 2025 07:00AM Tonix Pharmaceuticals Announces Presentation of New Data on Mpox and Smallpox Vaccine Candidate TNX-801 at the Vaccine Congress 2025
Jul 9, 2025 04:01PM Tonix publishes phase 3 fibromyalgia trial results in Pain Medicine
Jul 9, 2025 04:01PM Tonix Pharmaceuticals Announces On-line Publication of Phase 3 RESILIENT Trial Results of TNX-102 SL for Fibromyalgia in the Peer Reviewed Journal, Pain Medicine
Jul 7, 2025 07:03AM Tonix to present mpox vaccine data at Vienna congress
Jul 7, 2025 07:00AM Tonix Pharmaceuticals Announces Oral Presentation on Mpox and Smallpox vaccine candidate TNX-801 at the Vaccine Congress 2025
Jul 2, 2025 07:01AM Tonix Pharma (TNXP) Announces Peer-Reviewed Publication in Cancer Cell Journal Highlighting Positive Preclinical Data of mTNX-1700 in Gastric Cancer Animal Models
Jul 2, 2025 07:00AM Tonix Pharmaceuticals Announces Peer-Reviewed Publication in Cancer Cell Journal Highlighting Positive Preclinical Data of mTNX-1700 in Gastric Cancer Animal Models
Apr 16, 2025 07:00AM Tonix Pharmaceuticals Announces Oral Presentation and Panel Participation at the World Vaccine Congress Washington 2025
Apr 9, 2025 07:02AM Tonix Pharma (TNXP) and Makana Therapeutics Announce Collaboration Combining TNX-1500 with Makana’s Genetically Engineered Organs
Mar 24, 2025 08:04AM Tonix Pharma (TNXP) Announces that FDA Will Not Require an Advisory Committee Meeting to Discuss New Drug Application for TNX-102 SL
Mar 5, 2025 07:00AM Tonix Pharmaceuticals to Present at the 2025 Virtual Investor Summit
Feb 7, 2025 08:33AM Tonix Pharma (TNXP) Reports Prelim FY24 Results
Dec 23, 2024 08:01AM Tonix Pharma (TNXP) Announces PDUFA Goal Date of August 15, 2025, for FDA Decision on U.S. Marketing Approval for TNX-102
Dec 17, 2024 08:02AM Tonix Pharma (TNXP) Announces FDA Acceptance of the NDA for TNX-102
Nov 1, 2024 07:01AM Tonix Pharma (TNXP) Presented Data on Potential Mpox Vaccine TNX-801
Sep 27, 2024 07:00AM Tonix Pharma (TNXP) Issued US Patent Covering the Subcutaneous Delivery of FDA-Approved Zembrace® SymTouch to Treat Migraines
Sep 16, 2024 07:03AM Tonix Pharma (TNXP) Announces TNX-801 Aligns with WHO’s Newly Issued Preferred Target Product Profile for Mpox Vaccines in Global Health Emergency
Sep 14, 2017 07:10AM Tonix Pharma (TNXP) Appoints Margaret Bell to Board
View Older Stories